<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170792</url>
  </required_header>
  <id_info>
    <org_study_id>1160.16</org_study_id>
    <nct_id>NCT02170792</nct_id>
  </id_info>
  <brief_title>Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS</brief_title>
  <official_title>Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 50 or 200 mg BIBR 1048 MS Film-coated Tablet Over 2 Days With and Without Coadministration of Ranitidine to Healthy Subjects. Three Groups, 2-way Crossover, Randomised, Open Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the extent of absorption of 12.5, 50 and 200 mg of BIBR 1048 MS with and without
      coadministration of 150 mg ranitidine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <primary_completion_date type="Actual">March 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma drug concentration curve for BIBR 953 ZW from 0 to 12 hours (AUC0-12h)</measure>
    <time_frame>before and 0.5, 1, 1.5, 2, 4, 6 h after dosing on day 1 and before and 0.5, 1, 1.5, 2, 4, 6, 8, 12 h after dosing on day 2 of each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma drug concentration time curve of BIBR 953 ZW within the interval from zero time to tf (last quantifiable plasma concentration) (AUC0-tf)</measure>
    <time_frame>before and 0.5, 1, 1.5, 2, 4, 6 h after dosing on day 1 and before and 0.5, 1, 1.5, 2, 4, 6, 8, 12 h after dosing on day 2 of each treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of drug in plasma ( Cmax )</measure>
    <time_frame>before and 0.5, 1, 1.5 2, 4, 6 h after dosing on day 1 and before and 0.5, 1, 1.5, 2, 4, 6, 8, 12 h after dosing on day 2 of each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of the analyte in plasma (tmax)</measure>
    <time_frame>before and 0.5, 1, 1.5 2, 4, 6 h after dosing on day 1 and before and 0.5, 1, 1.5, 2, 4, 6, 8, 12 h after dosing on day 2 of each treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Pulse rate</measure>
    <time_frame>baseline up to 36 h after last administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood pressure (systolic and diastolic)</measure>
    <time_frame>baseline up to 36 h after last administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in ECG</measure>
    <time_frame>baseline up to 36 h after last administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in routine laboratory</measure>
    <time_frame>baseline up to 36 h after last administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 36 h after last administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in international normalized ratio (INR )</measure>
    <time_frame>before and 2 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in activated prothrombin time (aPTT)</measure>
    <time_frame>before and 2 hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBR 1048 MS with ranitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low, medium or high dose in combination with ranitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS without ranitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low, medium or high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS</intervention_name>
    <description>Low, medium or high dose</description>
    <arm_group_label>BIBR 1048 MS with ranitidine</arm_group_label>
    <arm_group_label>BIBR 1048 MS without ranitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranitidine</intervention_name>
    <description>150mg</description>
    <arm_group_label>BIBR 1048 MS with ranitidine</arm_group_label>
    <other_name>Zantic ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male subjects as determined by results of screening

          -  signed written informed consent in accordance with GCP and local legislation

          -  age &gt;= 18 and &lt;= 50 years

          -  Broca &gt;= - 20% and &lt;0 + 20%

        Exclusion Criteria:

          -  any finding of the medical examination (including blood pressure, pulse rate and ECG)

          -  history or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders

          -  history of orthostatic hypotension, fainting spells and blackouts

          -  diseases of central nervous system (such as epilepsy) or psychiatric disorders

          -  chronic or relevant acute infections

          -  History of:

               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the
                  trial as judged by the investigator

               -  any bleeding disorder including prolonged or habitual bleeding

               -  other hematologic disease

               -  cerebral bleeding (e.g. after a car accident)

               -  commotio cerebri

          -  intake of drugs with a long half-life (&gt;24 hours) within 1 month prior to
             administration

          -  use of any drugs which might influence the results of the trial within 10 days prior
             to administration or during administration

          -  participation in another trial with an investigational drug within 2 month prior to
             administration or during trial

          -  smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

          -  alcohol abuse (&gt;60 g / day)

          -  drug abuse

          -  blood donation within 1 month prior to administration or during the trial

          -  excessive physical activities within 5 days prior to administration or during the
             trial

          -  any laboratory value outside the clinically accepted reference range

          -  history of any familial bleeding disorder

          -  Thrombocytes &lt; 150000 /µl
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranitidine</mesh_term>
    <mesh_term>Ranitidine bismuth citrate</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

